Endotronix today announced plans to relocate and expand its headquarters in Naperville, Illinois to support a commercial launch of its heart failure treatment devices.
The company’s new building will significantly increase its manufacturing and operating capacity to grow its workforce by 30%. The new location also allows for continued expansion for its Cordella heart failure system and pulmonary artery sensor, which is pending FDA pre-market approval.
The 80,000 sq. foot facility more than doubles its current footprint. It is undergoing custom enhancements to include a state-of-the-art cleanroom, manufacturing, quality and administrative space. Endotronix expects the first phase of construction to be completed in early 2023 and will include a hybrid workspace designed to accommodate a flexible workforce.
“This is an exciting time for Endotronix. As we approach full enrollment in our Proactive-HF clinical trial, we are looking ahead toward scaling our manufacturing and operations in anticipation of commercialization of our proactive digital heart failure system,” CEO Harry Rowland said in a news release. “Naperville offers an ideal location to plant our roots, offering a skilled workforce, affordable quality of life for our employees, desirable proximity to Chicago, and strong sense of community.”
Endotronix plans to maintain its European office in Ireland.